QIAGEN Reports Second Quarter 2008 Results And ...

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this 
announcement. 
----------------------------------------------------------------------
--------------    




  * 61% Revenue Growth, 11% Organic Growth
  * 68% Adjusted Operating Income Growth
  * $0.20 Adjusted EPS

Venlo, The Netherlands, August 4,  2008 - QIAGEN N.V. (Nasdaq:  QGEN;
Frankfurt, Prime  Standard:  QIA)  today  announced  the  results  of
operations for the second quarter and the six-month period ended June
30, 2008.

The reported net sales for the second quarter 2008 were in line  with
and adjusted earnings per share exceeded the guidance provided by the
Company on May 6, 2008.

QIAGEN's  second  quarter  2008   results  include  the  results   of
operations of Digene Corporation and  eGene, Inc. as well as  certain
charges related to these acquisitions which occurred after the second
quarter of 2007.

Second Quarter and First Six-Month Period 2008 Results

The Company  reported  that consolidated  net  sales for  its  second
quarter 2008 increased 61% to $217.9 million from $135.0 million  for
the same quarter in 2007.  Reported operating income for the  quarter
increased 10%  to $34.0  million  from $31.0  million in  the  second
quarter of 2007, and net income for the second quarter 2008 increased
slightly to $23.2 million from $22.6  million in the same quarter  of
2007. Diluted earnings per share for the second quarter decreased  to
$0.11 in 2008  (based on  205.5 million weighted  average shares  and
share equivalents outstanding)  from $0.14  in 2007  (based on  156.9
million weighted average shares and share equivalents outstanding).
On an adjusted basis, second  quarter operating income increased  68%
to $60.6  million in  2008 from  $36.0 million  in 2007,  and  second
quarter adjusted net income  increased 57% to  $40.4 million in  2008
from $25.8  million  in 2007.  Adjusted  diluted earnings  per  share
increased to $0.20 in the second quarter 2008 from $0.16 in 2007.


QIAGEN's Second Quarter 2008 (in US$ millions, except per share
information)
                                     Q2 2008      Q2 2007      Growth

Net sales                              217.9        135.0         61%
Operating income, adj.                  60.6         36.0         68%
Net income, adj.                        40.4         25.8         57%
EPS, adj. (US$)                         0.20         0.16         25%

Adjusted figures excluding acquisition, integration and restructuring
related charges as well as amortization of acquired IP and
equity-based compensation (SFAS 123R) as detailed in the table below.


For the six-month period ended June 30, 2008, net sales increased 62%
to $425.0 million compared to $262.9 million in the comparable period
of 2007. Operating  income as  reported for  the first  half of  2008
increased 12% to $67.0 million from $59.8 million for the same period
in 2007, net income increased 3% to $43.6 million from $42.5  million
in 2007, and diluted  earnings per share decreased  to $0.21 in  2008
from $0.27 in 2007.

On an adjusted basis, operating income for the six-month period ended
June 30, 2008  increased 73%  to $119.2  million in  2008 from  $68.8
million in  2007, and  adjusted  net income  increased 60%  to  $77.3
million from $48.4  million. Adjusted diluted  earnings per share  in
the six months ended June 30,  2008 increased 23% to $0.38 per  share
from $0.31 per share in the same period of 2007.

QIAGEN has  regularly reported  adjusted results  to give  additional
insight into its  financial performance. Adjusted  results should  be
considered in addition to the reported results prepared in accordance
with generally  accepted accounting  principles,  but should  not  be
considered a substitute. The Company believes certain items should be
excluded from adjusted results  when they are  either outside of  our
ongoing core operations or vary significantly from period to  period,
which  affects  the  comparability  of  results  with  the  Company's
competitors and its  own prior  periods. Costs  and charges  excluded
from  adjusted   results   include  acquisition,   integration,   and
restructuring-related costs,  acquisition-related  amortization,  and
equity based compensation in  accordance with Statement of  Financial
Accounting Standards No. 123 (Revised) (SFAS 123R).


QIAGEN's Adjustments to Gross Profit, Operating
Income, Net Income and EPS
in US$
millions
unless
indicated         Q2 2008          Q2 2007           6M 2008          6M 2007

Gross profit             148.1             91.5             289.3            178.6
reported
Amortization              11.9              2.0              22.8              3.9
of acquired
IP
SFAS 123R                  0.3                                0.5
impact                                      -                                  -
Gross profit,            160.3             93.5             312.6            182.5
adjusted

Operating                 34.0             31.0              67.0             59.8
income,
reported
Acquisition                9.3              1.3              18.1              2.0
and
integration
related
charges
Relocation                 0.1              0.1               0.5              0.5
and
restructuring
charges
Amortization              14.8              2.7              29.2              5.3
of acquired
IP (incl.
COS)
SFAS 123R                  2.4              0.9               4.4              1.2
impact (incl.
COS)
Operating                 60.6             36.0             119.2             68.8
income,
adjusted

Net income,               23.2             22.6              43.6             42.5
reported
Acquisition                6.1              0.9              11.7              1.3
and
integration
related
charges
Relocation
and                        -                -                 0.3              0.4
restructuring
charges
Amortization               9.5              1.7              18.8              3.4
of acquired
IP
SFAS 123R                  1.6              0.6               2.9              0.8
impact
Net income,               40.4             25.8              77.3             48.4
adjusted

Weighted           205,475,000      156,902,000       205,300,000      156,550,000
average
number of
diluted
common shares
EPS, reported             0.11             0.14              0.21             0.27
in US$
EPS, adjusted             0.20             0.16              0.38             0.31
in US$


"QIAGEN experienced  a successful  second  quarter 2008,"  said  Peer
Schatz, QIAGEN's Chief Executive Officer. "We saw strong revenue  and
net income growth and continue to expand our leadership and strategic
position. We launched 19 new products in the area of sample and assay
technologies with a focus on  gene and protein function analysis  and
in June  also started  shipping  of our  new flagship  platform,  the
QIAsymphony which was launched in  January 2008 and already  received
significant interest from our customers across all segments. In  line
with our  projected  timelines,  in  July  we  transitioned  the  few
remaining projects  related to  the Digene  integration to  the  line
functions in the  organization and concluded  the Digene  integration
project in time and above target in terms of planned cost synergies."

"We  further  expanded  our  market  and  technology  leadership   in
molecular diagnostics by  adding two important  products to  QIAGEN's
instrumentation platform  through  the acquisition  of  Corbett  Life
Science in July this year.   Both products, the Rotor-Gene  real-time
PCR cycler and the CAS instrument,  a reaction set-up system, can  be
seamlessly combined  with  QIAGEN's  sample  and  assay  technologies
portfolio.  In  addition,  the   cycler  technology  can  easily   be
integrated into  the QIAsymphony  platform to  complete an  automated
system which covers  the whole  workflow from  sample preparation  to
result measurement in all key areas of PCR-based assay analysis."

"We are very pleased  with our financial  performance in this  second
quarter of 2008.  Reported revenues  were in line  with and  adjusted
earnings per share exceeded our expectations. We experienced a strong
adjusted operating margin increase to 28% in the second quarter  2008
which corresponds to a growth rate  of 68% year over year  reflecting
the achievement  of  cost  synergies  following  the  acquisition  of
Digene," said Roland Sackers, QIAGEN's Chief Financial Officer.

"Revenue growth for the  second quarter was 61%  and was fueled by  a
strong organic growth of  11% and a positive  contribution of 41%  at
constant currencies from acquisitions. Our sample and assay portfolio
contributed 64%  growth (55%  at constant  exchange rates).  QIAGEN's
instrumentation business  recorded  a  growth rate  of  39%  (30%  at
constant exchange rates) based on the new instruments  (QIAsymphonySP
and QIAxcel) which  started shipping during  the second quarter.  Net
sales in the Americas for the second quarter 2008 represented 49%  of
our overall  business and  recorded  a growth  rate  of 96%  (95%  at
constant currencies) while European sales, which represent 40% of our
revenues, showed  a growth  rate  of 38%  (22% at  constant  exchange
rates). Net sales in Asia remained  strong, showing a growth rate  of
35% (24% at constant exchange rates)."


Update on Guidance for Fiscal 2008

Based on the first six months and reflecting the revenue contribution
of approximately $14 million and the dilution of approximately  $0.02
to adjusted earnings per share related to the acquisition of  Corbett
Life Science, QIAGEN  updated its  guidance for the  full year  2008.
QIAGEN adjusted its revenue guidance for  fiscal 2008 to $889 -  $919
million and increased  its guidance for  adjusted earnings per  share
from adjusted $0.74 - $0.78 to $0.79 - $0.80.


QIAGEN's Second Quarter 2008 at
Constant Currencies
                    2008       2008       2007        Growth Rate
As percentage        Q2         Q2         Q2
of net sales,                Constant                       Constant
unless indicated  Reported   Currency   Reported  Reported  Currency

Consumables             90%        91%        89%       64%       55%
Instruments              9%         9%        10%       39%       30%
Others                   1%         0%         1%       41%       26%
Total revenues         100%       100%       100%       61%       52%

Gross margin            68%        68%        68%       62%       53%
Gross margin,
adj.                    74%        74%        69%       72%       63%

Operating income
margin                  16%        16%        23%       10%        8%
Operating income
margin, adj.            28%        29%        27%       68%       66%

Net income
margin                  11%        11%        17%        3%        2%
Net income
margin, adj.            19%        19%        19%       57%       55%

EPS in US$ per
share                  0.11       0.11       0.14      -21%      -21%
EPS in US$ per
share, adj.            0.20       0.19       0.16       25%       19%

Adjusted figures excluding acquisition, integration and restructuring
related charges as well as amortization of acquired IP and
equity-based compensation (SFAS 123R) - as detailed in the table
above.


Detailed information on QIAGEN's  business and financial  performance
will be presented in its conference call on August 5, 2008 at  9:30am
ET. The  corresponding  presentation  slides will  be  available  for
download on QIAGEN's website at www.qiagen.com/goto/050808. A webcast
of the  conference call  will be  available on  the same  website  at
www.qiagen.com/goto/050808.


QIAGEN - Sample and Assay Technologies Highlights:


  * QIAGEN acquired Corbett Life Science Pty. Ltd., a privately-held
    developer, manufacturer, and distributor of life sciences
    instrumentation headquartered in Sydney, Australia on July 1.
    Corbett is best known for the world's first rotary real-time PCR
    cycler system - the Rotor-Gene(TM) - a system used to detect and
    measure real-time polymerase chain reaction (PCR) reactions. The
    addition of this proprietary PCR detection technology extends
    QIAGEN's molecular testing solution portfolio and enhances
    QIAGEN's options to offer sample and assay technology solutions
    spanning from sample to result. The Corbett Rotor-Gene real-time
    PCR cycler is an excellent complement to QIAGEN's portfolio of
    current and future molecular testing solutions, including its
    modular processing platform QIAsymphony. Shortly prior to the
    acquisition of Corbett by QIAGEN, Corbett acquired a license for
    certain Idaho Technologies patents related to real-time PCR
    instrumentation and applications.

  * QIAGEN launched 19 new products in the area of sample & assay
    technologies including a series of innovative products for micro
    RNA (miRNA) and epigenetic processing and analysis. In addition,
    QIAGEN launched a number of assay technologies including two
    CE-marked tests (HIV-1 and borrelia) as well as tests for the
    applied testing markets (bovine virus diarrhea virus (BVD) in
    cattle and Taylorella equigenitalis in horses).

  * The German Association of Gynaecology and Obstetrics (Deutsche
    Gesellschaft für Gynäkologie und Geburtshilfe, DGGG) announced
    clinical guidelines "S-2-guidelines for the prevention,
    diagnostic and therapy of HPV infections and pre-invasive lesions
    of female genitals" and recommend the implementation of an HPV
    test in conjunction with the Pap Smear test for routine screening
    of women age 30 and above in Germany. The reimbursement and the
    implementation of the HPV test with routine screening "will help
    to identify pre-stages of cervical cancer that are treatable and
    at the same time will avoid more significant surgeries with
    patients when presenting late-stage symptoms of cervical
    cancer."


About QIAGEN:

QIAGEN   N.V.,    a    Netherlands   holding    company,    is    the
leading global provider of  sample  and  assay  technologies.  Sample
technologies are used to  isolate and process  DNA, RNA and  proteins
from biological samples such  as blood or tissue. Assay  technologies
are used  to  make such  isolated  biomolecules visible.  QIAGEN  has
developed and markets more than 500 sample and assay products as well
as automated solutions for such consumables. The company provides its
products to molecular diagnostics laboratories, academic researchers,
pharmaceutical   and    biotechnology    companies,    and    applied
testing customers for  purposes such  as forensics,  animal  or  food
testing   and   pharmaceutical   process   control. QIAGEN's    assay
technologies  include  one  of  the  broadest  panels  of   molecular
diagnostic tests available  worldwide. This panel  includes the  only
FDA-approved test for human  papillomavirus (HPV), the primary  cause
of cervical cancer. QIAGEN employs more than 2,800 people in over  30
locations worldwide. Further information about QIAGEN can be found at
www.qiagen.com.

Certain of  the statements  contained  in this  news release  may  be
considered forward-looking statements within  the meaning of  Section
27A of the U.S. Securities Act  of 1933, as amended, and Section  21E
of the  U.S. Securities  Exchange Act  of 1934,  as amended.  To  the
extent that  any  of  the statements  contained  herein  relating  to
QIAGEN's  products,  markets,  strategy  or  operating  results   are
forward-looking, such statements  are based  on current  expectations
that involve a number of uncertainties and risks. Such  uncertainties
and risks  include, but  are not  limited to,  risks associated  with
management of  growth  and international  operations  (including  the
effects  of  currency  fluctuations   and  risks  of  dependency   on
logistics),  variability   of  operating   results,  the   commercial
development of the applied testing markets, clinical research markets
and proteomics markets, women's  health/HPV testing markets,  nucleic
acid-based molecular diagnostics market, and genetic vaccination  and
gene  therapy   markets,  changing   relationships  with   customers,
suppliers and strategic  partners, competition,  rapid or  unexpected
changes in technologies, fluctuations in demand for QIAGEN's products
(including fluctuations due  to the  level and  timing of  customers'
funding,  budgets,  and  other   factors),  our  ability  to   obtain
regulatory approval of our infectious disease panels, difficulties in
successfully adapting QIAGEN's products  to integrated solutions  and
producing such  products,  the  ability of  QIAGEN  to  identify  and
develop  new  products  and   to  differentiate  its  products   from
competitors' products, market acceptance of QIAGEN's new products and
the integration of acquired technologies and businesses. For  further
information, refer  to the  discussions in  reports that  QIAGEN  has
filed with,  or  furnished  to,  the  U.S.  Securities  and  Exchange
Commission (SEC).

                                 ###


                             QIAGEN N.V.
             CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                             (unaudited)


                                                  Three months
(in US$ thousands, except per share
data)                                            ended June 30,

                                              2008           2007
                                                 $              $
Net sales                                      217,888        135,039
Cost of sales                                   57,863         41,577
Cost of sales - acquisition related             11,949          1,943
intangible amortization
  Gross profit                                 148,076         91,519

Operating Expenses:
  Research and development                      23,840         12,690
  Sales and marketing                           57,696         31,995
  General and administrative                    20,297         13,666
  Acquisition, integration and related           9,342          1,346
costs
  Acquisition related intangible                    74             70
amortization
  Relocation and restructuring costs             2,816            715
Total operating expenses                       114,065         60,482

Income from operations                          34,011         31,037

Other Income (Expense):
  Interest income                                2,324          5,260
  (Interest expense)                           (9,187)        (4,923)
  Other income, net                                424          1,135
Total other income (expense)                   (6,439)          1,472

  Income before provision for income            27,572         32,509
taxes and minority interest
  Provision for income taxes                    4,291          9,926
  Minority interest                                 56              -
                                                 $       $     22,583
  Net income                                    23,225


  Weighted average number of diluted           205,475        156,902
common shares

  Diluted net income per common share       $     0.11     $     0.14

  Diluted net income per common share       $     0.20    $      0.16
excluding acquisition, integration and
restructuring related
charges as well as amortization of
acquired IP and
equity-based compensation (SFAS 123R)




                             QIAGEN N.V.
             CONDENSED CONSOLIDATED STATEMENTS OF INCOME
                             (unaudited)


                                                Six months
(in US$ thousands, except per share
data)                                         ended June 30,

                                           2008             2007
Net sales                              $     424,994    $     262,918
Cost of sales                                112,919           80,506
Cost of sales - acquisition related           22,775            3,850
intangible amortization
  Gross profit                               289,300          178,562

Operating Expenses:
  Research and development                    45,209           24,221
  Sales and marketing                        111,774           63,298
  General and administrative                  40,201           27,290
  Acquisition, integration and                18,067            2,036
related costs
  Acquisition related intangible                 534              478
amortization
  Relocation and restructuring                 6,466            1,406
costs
Total operating expenses                     222,251          118,729

Income from operations                        67,049           59,833

Other Income (Expense):
  Interest income                             5,296           10,426
  (Interest expense)                        (19,637)          (9,614)
  Other income, net                           2,559              881
Total other income (expense)                (11,782)           1,693

  Income before provision for                55,267           61,526
income taxes and minority interest
  Provision for income taxes                 11,592           19,076
  Minority interest                             116                 -
  Net income                            $     43,559     $     42,450


  Weighted average number of                 205,300          156,550
diluted common shares

  Diluted net income per common           $     0.21       $     0.27
share

Diluted net income per common share       $     0.38       $     0.31
excluding acquisition, integration
and restructuring related
charges as well as amortization of
acquired IP and equity-
based compensation (SFAS 123R)



                                 QIAGEN N.V.
                    CONDENSED CONSOLIDATED BALANCE SHEETS


                                           June 30,         December 31,
                                             2008               2007
(in thousands US$)                        (unaudited)

Assets

Current Assets:
          Cash and cash equivalents       $     380,667       $     347,320
          Marketable securities                       -               2,313
          Notes receivable                        3,482               5,139
          Accounts receivable, net              148,675             136,707
          Income taxes receivable                17,805              10,696
          Inventories                           107,768              88,346
          Deferred income taxes                  38,697              23,732
          Prepaid expenses and other             38,277              33,693
                    Total current               735,371             647,946
                    assets

Long-Term Assets:
          Property, plant and                   301,040             283,491
          equipment, net
          Goodwill                            1,116,518           1,107,882
          Intangible assets, net                618,908             639,107
          Deferred income taxes                  69,836              72,128
          Other assets                           31,859              24,620
                    Total long-term           2,138,161           2,127,228
                    assets

             Total assets                 $   2,873,532       $   2,775,174

Liabilities and Shareholders' Equity

Current Liabilities:
                                         $                 $
          Short term loans                          -                     4
          Current portion of capital              2,956               2,769
          lease obligations
          Accounts payable                       39,354              40,379
          Accrued and other                     108,689             104,220
          liabilities
          Income taxes payable                   25,290              13,456
          Deferred income taxes                   6,628               4,903
                    Total current               182,917             165,731
                    liabilities

Long-Term Liabilities:
          Long-term debt, net of                950,000             950,000
          current portion
          Capital lease obligations,             32,441              33,017
          net of current portion
          Deferred income taxes                 217,909             225,893
          Other                                  10,567               8,405
                    Total long-term           1,210,917           1,217,315
                    liabilities

Minority interest in consolidated                   669                 553
subsidiaries

Shareholders' Equity:
          Common shares, EUR .01 par
          value:
             Authorized--410,000,000
             shares
             Issued and
             outstanding--196,519,000
             shares
                in 2008 and                       2,193               2,175
             195,335,000 shares in
             2007
             Additional                         942,701             925,597
             paid-in-capital
             Retained earnings                  432,338             388,779
             Accumulated other                  101,797              75,024
             comprehensive income
                    Total                     1,479,029           1,391,575
                    shareholders'
                    equity

             Total liabilities and                   $      $     2,775,174
             shareholders' equity             2,873,532


Contacts:


Roland Sackers                Dr. Solveigh Mähler
Chief Financial Officer       Director Investor Relations
QIAGEN N.V.                   QIAGEN N.V.
e-mail:                       [phone]
[e-mail]     e-mail: [e-mail]

                              Albert F. Fleury
                              Associate Director Investor Relations
                              North America
                              QIAGEN N.V.
                              [phone]
                              e-mail: [e-mail]


 
--- End of Message ---

Qiagen N.V.
Spoorstraat 50 KJ Venlo Netherlands

WKN: 901626; ISIN: 
NL0000240000; Index: HDAX, MIDCAP, Prime All Share, TECH All Share, 
TecDAX;
Listed: Prime Standard in Frankfurter Wertpapierbörse, Freiverkehr in 
Börse Berlin, 
Freiverkehr in Börse Düsseldorf, Freiverkehr in Hanseatische 
Wertpapierbörse zu Hamburg, 
Freiverkehr in Niedersächsische Börse zu Hannover, Freiverkehr in 
Bayerische Börse München, 
Freiverkehr in Börse Stuttgart;